
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is actively collaborating and expanding its reach in the biopharmaceutical industry, with partnerships in clinical trials and biomarker development. With promising financials, strong market presence, and strategic developments, the company is poised for long-term growth and success in the field of liquid biopsy and precision oncology. Through their innovative technology and valuable services, Guardant Health is well-positioned to capture a significant share of the growing market for liquid-based cancer tests.
Bears say
Guardant Health is facing several challenges in the future, including unexpected competition in the precision oncology diagnostics market, a crowded market for MRD testing, and the potential for delays in commercializing its upcoming tests. Additionally, the company has a history of burning through large amounts of cash, with a goal of breakeven by 2027. The company may also face balance sheet risks if it decides to raise additional capital in order to make further investments.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares